e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
Xiaoping Long, Xuan He, Shinichiro Ohshimo, Matthias Griese, Rafael Sarria, Josune Guzman, Ulrich Costabel, Francesco Bonella
Source:
Eur Respir J , 49 (2) 1501924; DOI: 10.1183/13993003.01924-2015
Journal Issue:
February
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Xiaoping Long, Xuan He, Shinichiro Ohshimo, Matthias Griese, Rafael Sarria, Josune Guzman, Ulrich Costabel, Francesco Bonella. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J , 49 (2) 1501924; DOI: 10.1183/13993003.01924-2015
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
HISTOLOGICAL FINDINGS IN TRANSBRONCHIAL CRYOBIOPSIES OBTAINED FROM PATIENTS AFTER COVID-19
Does “UIPAF” really exist?
Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis
Related content which might interest you:
Serum CC16 is a potential predictor for IPF diagnosis and prognosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis.
Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases
Year: 2019
Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection
Source: Virtual Congress 2021 – COVID - 19 biomarkers
Year: 2021
Levels of YKL-40 in serum and sputum of patients diagnosed with hypersensitivity pneumonitis: A pilot study.
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Year: 2018
Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Serum KL-6 elevation related with severity in patients with pneumocystis pneumonia
Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies
Year: 2011
The serum YKL-40 is a useful biomarker for asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Circulating fetuin-A as a biomarker predicting mortality in ICU septic patients
Source: International Congress 2017 – Sepsis, infections, ARDS and beyond
Year: 2017
The relationship between the serum YKL-40 level and severity of asthma
Source: Annual Congress 2012 - Asthma management
Year: 2012
Serum and BAL levels of KL6 in chronic hypersensitivity pneumonitis Serum and BAL levels of KL6 in chronic hypersensitivity pneumonitis
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis
Source: Eur Respir J 2014; 43: 1530-1532
Year: 2014
Fibrinogen like the predictor of COVID-19 pneumonia progression
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021
Elevated blood eosinophils on admission for a severe exacerbation of COPD is not a predictor for survival
Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer
Year: 2017
Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Factors predicting response to azathioprine in chronic hypersensitivity pneumonitis – the importance of BAL lymphocytosis
Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Year: 2018
BAL neutrophilia as a predictor factor on IPF mortality
Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Year: 2010
Analysis of IgE and C-reactive protein as possible predictors of exacerbation patients with asthma
Source: Annual Congress 2011 - Biomarkers of allergic inflammation
Year: 2011
Is YKL-40 a prognostic marker in sarcoidosis?
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept